Incidence of acute otitis media in children < 16 years old in Germany during 2014-2019.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
13 04 2022
Historique:
received: 31 08 2021
accepted: 28 03 2022
entrez: 14 4 2022
pubmed: 15 4 2022
medline: 16 4 2022
Statut: epublish

Résumé

Acute otitis media (AOM) remains a common infection in children despite the introduction of pneumococcal conjugate vaccines. This study estimated AOM incidence rates (IRs) over time in children < 16 years old in Germany following PCV13 introduction. AOM episodes were identified in the InGef healthcare claims database from 2014-2019 in children aged < 16 years. Each AOM episode was classified as either simple or recurrent. Recurrent AOM was defined as 3 or more episodes identified within a 6-month period; or 4 or more episodes within a 12-month period with at least one episode in the prior 6 months. AOM-related surgical procedures within 12 months and complications within 21 days of an AOM episode were also identified. Annual IRs were calculated as number of episodes/child-years (CY) at risk. 95% Confidence intervals (95%CI) were calculated using the Wilson method. The Mann-Kendall test was used to assess trends over time. Between 2014 and 2019, the study population comprised 916,805 children with 327,726 AOM episodes, of which 15% (49,011) of all episodes were identified as recurrent AOM and 85% (278,715) as simple AOM. There were significant declines in AOM (p = 0.003) in the study population overall and in all age groups over the study period; from 101 (95%CI 101-102)/1000 CY to 79 (95%CI 78-80)/1000 CY in the total study population, from 209 (95%CI 206-212)/1000 CY to 147 (95%CI 145-150)/1000 CY in < 2-year-olds, from 239 (95%CI 237-242) to 179 (95%CI 177-182)/1000 CY in 2-4-year-olds, and from 50 (95%CI 49-50) to 38 (95%CI 37-39)/1000 CY in 5-15-year-olds. No significant trends were identified for AOM-related surgical procedures over the study period; however, AOM-related complications overall increased (p = 0.003). Between 2014 and 2019, AOM incidence overall declined in children aged 0-15 years in Germany. Over the study period, the incidence of complicated AOM cases increased, however the incidence of AOM-related surgical procedures remained constant. Despite the impact of PCV13, the burden associated with AOM in Germany remains substantial.

Sections du résumé

BACKGROUND
Acute otitis media (AOM) remains a common infection in children despite the introduction of pneumococcal conjugate vaccines. This study estimated AOM incidence rates (IRs) over time in children < 16 years old in Germany following PCV13 introduction.
METHODS
AOM episodes were identified in the InGef healthcare claims database from 2014-2019 in children aged < 16 years. Each AOM episode was classified as either simple or recurrent. Recurrent AOM was defined as 3 or more episodes identified within a 6-month period; or 4 or more episodes within a 12-month period with at least one episode in the prior 6 months. AOM-related surgical procedures within 12 months and complications within 21 days of an AOM episode were also identified. Annual IRs were calculated as number of episodes/child-years (CY) at risk. 95% Confidence intervals (95%CI) were calculated using the Wilson method. The Mann-Kendall test was used to assess trends over time.
RESULTS
Between 2014 and 2019, the study population comprised 916,805 children with 327,726 AOM episodes, of which 15% (49,011) of all episodes were identified as recurrent AOM and 85% (278,715) as simple AOM. There were significant declines in AOM (p = 0.003) in the study population overall and in all age groups over the study period; from 101 (95%CI 101-102)/1000 CY to 79 (95%CI 78-80)/1000 CY in the total study population, from 209 (95%CI 206-212)/1000 CY to 147 (95%CI 145-150)/1000 CY in < 2-year-olds, from 239 (95%CI 237-242) to 179 (95%CI 177-182)/1000 CY in 2-4-year-olds, and from 50 (95%CI 49-50) to 38 (95%CI 37-39)/1000 CY in 5-15-year-olds. No significant trends were identified for AOM-related surgical procedures over the study period; however, AOM-related complications overall increased (p = 0.003).
CONCLUSION
Between 2014 and 2019, AOM incidence overall declined in children aged 0-15 years in Germany. Over the study period, the incidence of complicated AOM cases increased, however the incidence of AOM-related surgical procedures remained constant. Despite the impact of PCV13, the burden associated with AOM in Germany remains substantial.

Identifiants

pubmed: 35418046
doi: 10.1186/s12887-022-03270-w
pii: 10.1186/s12887-022-03270-w
pmc: PMC9006409
doi:

Substances chimiques

Pneumococcal Vaccines 0
Vaccines, Conjugate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

204

Informations de copyright

© 2022. The Author(s).

Références

Pediatr Infect Dis J. 2014 May;33(5):453-7
pubmed: 24732389
Ear Nose Throat J. 2021 Jun;100(3_suppl):325S-332S
pubmed: 32579395
J Antimicrob Chemother. 2004 Feb;53(2):361-6
pubmed: 14729760
Epidemiol Infect. 2014 Aug;142(8):1778-88
pubmed: 24330917
J Antimicrob Chemother. 2021 Aug 12;76(9):2419-2427
pubmed: 34021757
Pediatr Infect Dis J. 2020 Aug;39(8):763-770
pubmed: 32639460
Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):638-41
pubmed: 19620582
Nat Rev Dis Primers. 2016 Sep 08;2:16063
pubmed: 27604644
BMC Infect Dis. 2012 Nov 20;12:312
pubmed: 23167692
Pediatrics. 2017 Sep;140(3):
pubmed: 28784702
BMC Health Serv Res. 2018 May 2;18(1):318
pubmed: 29720156
J Laryngol Otol. 2013 Jan;127 Suppl 1:S30-4
pubmed: 23186827
Otolaryngol Clin North Am. 1991 Aug;24(4):757-61
pubmed: 1870869
BMC Infect Dis. 2015 May 05;15:207
pubmed: 25940580
JAMA Pediatr. 2014 Jan;168(1):68-75
pubmed: 24276262
Dtsch Arztebl Int. 2014 Feb 28;111(9):151-9; quiz 160
pubmed: 24661591
BMC Health Serv Res. 2021 Mar 4;21(1):193
pubmed: 33663491
Epidemiol Infect. 1998 Dec;121(3):529-34
pubmed: 10030701
Vaccine. 2010 Nov 19;28 Suppl 6:G39-52
pubmed: 21075269
BMC Infect Dis. 2016 Aug 11;16(1):407
pubmed: 27514843
BMC Health Serv Res. 2018 Sep 14;18(1):715
pubmed: 30217156
Expert Rev Anti Infect Ther. 2014 Sep;12(9):1159-63
pubmed: 25075863
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
Pediatr Infect Dis J. 2017 Mar;36(3):274-281
pubmed: 27918383
Otolaryngol Head Neck Surg. 2017 May;156(5):938-945
pubmed: 28349737
Eur J Pediatr. 2015 Mar;174(3):355-64
pubmed: 25169065
Int J Pediatr Otorhinolaryngol. 2017 Oct;101:249-253
pubmed: 28964304
J Infect Dis. 1989 Jul;160(1):83-94
pubmed: 2732519
BMC Pediatr. 2012 Nov 29;12:185
pubmed: 23190626
BMC Pediatr. 2016 Jul 26;16:108
pubmed: 27457584
Clin Vaccine Immunol. 2014 Aug;21(8):1189-91
pubmed: 24920600
BMC Med. 2014 Jun 26;12:107
pubmed: 24965189
J Pediatr. 2021 Aug;235:233-238.e3
pubmed: 33894263
Otol Neurotol. 2018 Sep;39(8):1005-1011
pubmed: 30113560
Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):749-54
pubmed: 20432051
Front Med (Lausanne). 2021 May 20;8:675225
pubmed: 34095179
An Pediatr (Barc). 2004 Nov;61(5):408-12
pubmed: 15530320
Hum Vaccin Immunother. 2022 Dec 31;18(1):1942712
pubmed: 34319865
Pediatr Infect Dis J. 2017 Nov;36(11):1027-1031
pubmed: 28657970
J Med Microbiol. 2015 Oct;64(10):1103-1116
pubmed: 26248613
Int J Pediatr Otorhinolaryngol. 2014 Oct;78(10):1599-604
pubmed: 25074345
Acta Biomed. 2020 Feb 17;91(1-S):54-59
pubmed: 32073562
BMJ Open. 2020 May 5;10(5):e035343
pubmed: 32371515

Auteurs

Tianyan Hu (T)

Merck & Co., Inc, Kenilworth, NJ, USA. hutianyan@gmail.com.

Bélène Podmore (B)

OXON Epidemiology, London, UK.
London School of Hygiene & Tropical Medicine, London, UK.

Rosemarie Barnett (R)

OXON Epidemiology, London, UK.
University of Bath, Bath, UK.

Dominik Beier (D)

InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany.

Wolfgang Galetzka (W)

InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany.

Nawab Qizilbash (N)

OXON Epidemiology, London, UK.
London School of Hygiene & Tropical Medicine, London, UK.

Dennis Haeckl (D)

WIG2 GmbH, Leipzig, Germany.

Jessica Weaver (J)

Merck & Co., Inc, Kenilworth, NJ, USA.

Timo Boellinger (T)

MSD Sharp & Dohme GmbH, Haar, Germany.

Sarah Mihm (S)

MSD Sharp & Dohme GmbH, Haar, Germany.

Tanaz Petigara (T)

Merck & Co., Inc, Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH